The assay can be used to identify patients suitable for treatment with ALK-targeted therapeutics such as Pfizer's Xalkori.
The firm is now launching the test in Europe, supported by results from a multicenter prospective study showing high sensitivity in detecting bladder cancer.
The company's Barocycler 2320Extreme is now available to the European biopharma market.
The European Commission has now approved the anti-PD-1 therapy Keytruda, and the Dako test with it, as a first-line treatment for non-small cell lung cancer.
Illumina said the registration for its analysis software is the first step toward launching a full CE-IVD VeriSeq NIPT assay in Europe.
The firm received the CE IVD mark for Amplidiag Easy, an automated system that enables nucleic acid extraction and PCR setup directly from stool samples.
The firm said that it has completed clinical trials for the Group B Strep assay for the FDA and will start trials for the C. difficile test this month.
The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.
The test combines two previously CE marked assays that are based on the company's Nucleosomics platform for identifying and quantifying nucleosome structural features.
The combination of the new test with Biocartis' existing KRAS assay offers customers a complete solution for testing metastatic colorectal cancers as reccomended by professional guidelines.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.